<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.4.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art540.dtd?><?SourceDTD.Version 5.4.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_TJEM60010 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Turk J Emerg Med</journal-id><journal-id journal-id-type="iso-abbrev">Turk J Emerg Med</journal-id><journal-title-group><journal-title>Turkish Journal of Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">2452-2473</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4910139</article-id><article-id pub-id-type="publisher-id">S2452-2473(16)60059-6</article-id><article-id pub-id-type="doi">10.5505/1304.7361.2015.19970</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Communicable Diseases and Outbreak Control</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>AMELI</surname><given-names>Jonathan</given-names></name><email>jrzameli@gmail.com</email><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, USA</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Jonathan AMELI, M.D. Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02912<bold>Correspondence:</bold> Jonathan AMELI, M.D.Department of Emergency MedicineThe Warren Alpert Medical School of Brown UniversityProvidenceRI02912 <email>jrzameli@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>3</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>10</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>09</day><month>3</month><year>2016</year></pub-date><volume>15</volume><issue>Suppl 1</issue><fpage>20</fpage><lpage>26</lpage><permissions><copyright-statement>&#x000a9; 2015 Emergency Medicine Association of Turkey. Production and Hosting by Elsevier B.V. Originally published in [2015] by Kare Publishing.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Emergency Medicine Association of Turkey</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ceab10"><title>SUMMARY</title><p>Infectious disease during an emergency condition can raise the death rate 60 times in comparison to other causes including trauma. An epidemic, or outbreak, can occur when several aspects of the agent (pathogen), population (hosts), and the environment create an ideal situation for spread. Overcrowding, poor regional design and hygiene due to poverty, dirty drinking water, rapid climate changes, and natural disasters, can lead to conditions that allow easier transmission of disease. Once it has been established that an emergency condition exists, there must be a prompt and thorough response for communicable disease control. A camp should be created, and the disease managed rapidly. The overall goals are rapid assessment, prevention, surveillance, outbreak control, and disease management.</p></abstract><kwd-group id="cekeyws10"><title>Keywords</title><kwd>Communicable disease</kwd><kwd>outbreak control</kwd><kwd>disaster</kwd><kwd>prevention</kwd><kwd>surveillance</kwd></kwd-group></article-meta></front><body><sec id="cesec10"><title>Introduction</title><p>Infectious or communicable disease can be defined as an illness caused by another living agent, or its products, that can be spread from one person to another.<xref rid="bib1" ref-type="bibr"><sup>[1]</sup></xref> An emergency condition can be defined as a state of disarray that has occurred during or after a regional conflict, or a natural disaster (i.e.: flood, earthquake, hurricane, drought).</p><p>Infectious disease during an emergency condition can raise the death rate 60 times in comparison to other causes including trauma.<xref rid="bib2" ref-type="bibr"><sup>[2]</sup></xref> Greater than 40% of deaths in emergency conditions occur secondary to diarrheal illness with 80% of those involving children less than 2 years of age.<xref rid="bib3" ref-type="bibr"><sup>[3]</sup></xref></p><p>Of note, there is no dependable performance assessment tool in improving communicable disease surveillance in regards to outbreaks of infectious disease although the Centers for Disease Control (CDC) has proposed viable mechanisms for public health in general.<xref rid="bib1" ref-type="bibr"><sup>[1]</sup></xref></p></sec><sec id="cesec20"><title>Emergency Department Precautions</title><p>The emergency department (ED) is the front line response system in many developed countries, and can act as the primary entry method for several communicable diseases. Prevention of transmission is paramount in keeping the ED a safe environment and limiting spread.</p><p>Hand hygiene prevents harboring transient flora (including <italic>Staphylococcus aureus, Clostridium difficile</italic> among others) by reduction of bacterial counts. The recommendation is to use alcohol-based materials such as foam with an alcohol by volume of 60-70%, or if suspected C. difficile, hand washing with vigorous physical manipulation to reduce the amount of spores of pathogens.<xref rid="bib4" ref-type="bibr"><sup>[4]</sup></xref> This must be coupled with Standard Precautions, which involves the use of barriers such as gloves, gowns, masks, and eye wear, in order to prevent infection of the healthcare worker.<xref rid="bib4" ref-type="bibr"><sup>[4]</sup></xref></p><p>Other safeguards such as airborne droplet, regular droplet, and contact precautions are necessary to prevent spread of unique vectors. Airborne particles are small (less than or equal to 5 micrometers), and remain in the air for several hours. Measles and Tuberculosis (TB) among others are transmitted via airborne particles. N95 mask or powered air-purifying respirators are required.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> Isolation rooms that have high ventilation (several changes in the air system per hour), and negative pressure should also be used.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib6" ref-type="bibr">6</xref></p><p>Large particle droplet transmission occurs with vectors such as <italic>Haemophilus influenzae,</italic> Group A <italic>Streptococcus,</italic> and <italic>Bordetella pertussis</italic> among many others.<xref rid="bib4" ref-type="bibr"><sup>[4]</sup></xref> Patients suspected of meningitis or a respiratory infection that does not qualify under airborne should wear a surgical mask, in addition to the provider, and this is usually sufficient to prevent major spread. If able, a separate room or at least an area blocked by curtains is preferred.<xref rid="bib5" ref-type="bibr"><sup>[5]</sup></xref></p><p>Contact precautions are used for pathogens infecting mucosal or skin surfaces such as S. aureus, Methicillin Resistant <italic>S. Aureus</italic> (MRSA), or <italic>C. Difficile.</italic> Use of protective gowns and gloves is usually sufficient unless suspicion of a higher level of precautions exists.<xref rid="bib5" ref-type="bibr"><sup>[5]</sup></xref></p><p>Vaccinating health care personnel against pathogens including, but not limited to, Hepatitis B, Measles, Mumps, Rubella, Pertussis, Varicella, and Seasonal Influenza, is highly efficient in decreasing the risk of transmission of many infectious diseases.<xref rid="bib7" ref-type="bibr"><sup>[7]</sup></xref> This is not a replacement for standard precautions, airborne, droplet, contact precautions, or hand hygiene, but is another measure of safety to undertake.<xref rid="bib4" ref-type="bibr"><sup>[4]</sup></xref></p></sec><sec id="cesec30"><title>Communicable Disease Control</title><p>An epidemic, or outbreak, can occur when several aspects of the agent (pathogen), population (hosts), and the environment create an ideal situation for spread. Infectious agents are plentiful, mutate rapidly, and can become resistant to drugs if not destroyed completely. Low vaccination rates, poor nutrition, age (young and elderly), and immunosuppression all contribute to infectious risk. Overcrowding, poor regional design and hygiene due to poverty, dirty drinking water, rapid climate changes, and natural disasters, can lead to conditions that allow easier transmission of disease.<xref rid="bib3" ref-type="bibr"><sup>[3]</sup></xref></p><p>Once it has been established that an emergency condition exists, there must be a prompt and thorough response for communicable disease control. A camp should be created, and the disease managed rapidly. The overall goals are rapid assessment, prevention, surveillance, outbreak control, and disease management. For more detailed information on the logistics of communicable disease control, please view the World Health Organization (WHO) field manual.<xref rid="bib8" ref-type="bibr"><sup>[8]</sup></xref></p></sec><sec id="cesec40"><title>Rapid Assessment</title><p>&#x0201c;Rapid assessment&#x0201d; involves identification of the main disease, and obtaining detailed information about the host country in less than four days.</p><p>First, compose the team. This will include public health experts in addition to experts in other fields such as sanitation, nutrition, and statistics. Second, assign tasks, and communicate thoroughly with the host country. Third, prepare a systematic method for data collection alongside statisticians. Data should focus on security, mapping the site, morbidity, mortality, demography, food availability, nutritional status, water, and sanitation among many other topics. Additionally, coordinate a visual inspection of the area prior to arrival, and interview key leaders of the area. This data should be clear, concise, goal-oriented, standardized, timely, and widely distributed to the team and all involved organizations. This will help guarantee appropriate funding, and communication with the host country.</p></sec><sec id="cesec50"><title>Prevention</title><p>&#x0201c;Prevention&#x0201d; involves shelter, site planning, cleanliness, vaccination, vector control, and education.</p><p>First, shelter and site planning, involves creating an environment that will avoid packing together individuals tightly as well as avoiding areas with high vector transmission, poor water supply, low security, poor vegetation and soil, and low ability for access (ie: close enough to a major center, but not so far as to make travel impossible).</p><p>Second, cleanliness covers many aspects of what has already been discussed in the emergency room setting. Of note, full biohazard precautions should be taken with viral hemorrhagic fevers such as Ebola (to be discussed below).</p><p>Water must be available for up to seven liters per person per day (in the most extreme situations), and it must be clean. This can rise up to 20 liters per person per day if taking into account bathing as well as cooking. Diseases spread in contaminated water are plentiful, and their evasion is of utmost importance in emergency conditions. Biological quality (less than 10 fecal coliforms per 100 ml of water) is important. Chlorine can be used to disinfect water. Chemical quality is of less importance than biological quality.</p><p>Waste disposal is important.<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> Areas for excretion should not be near water sources, and they should be maintained with detail for sanitation. Pits to dispose of the contents should be created. Solid waste should be buried and/or burned. Liquid waste (ie: bathing) should be diverted into either storm water drains, or if in a dry area, to an isolated, separate pond, for disposal at a later time. Medical waste could be incinerated, preferably near the camp itself, making sure the contents do not travel to other dwellings. Otherwise, they should be buried after being sealed in a metal container.</p><p>Disposing of the dead involves burial to at least 1 meter below earth. In most cases, the bodies should be wrapped in a body bag. Full biohazard precautions should be undertaken for diseases such as Ebola during burial. The clothing and other contact items of the deceased should be burned. With cholera, and other diarrheal illnesses, the bodies should be disinfected with 2% chlorine solution.</p><p>Controlling vectors such as mosquitos (Malaria, Dengue, others) is essential to reduce specific disease transmission. For mosquitos, chemical environmental control, and use of mosquito nets treated with insecticide and repellent sprays are crucial. For Malaria, prophylactic drugs can be used. Environmental sanitation is important for Filariasis to prevent breeding of the Culex spp. mosquitos. For other vectors such as flies, mites, lice, and fleas, hygiene, insecticide and repellants are key factors in prevention of disease.</p><p>Food supply for poor, underdeveloped nations is crucial in preventing disease. A person with malnutrition will be immunosuppressed and more likely to contract disease as well as less likely to survive the physical toll of any infectious disease. In addition, as with water, sanitation of food is key, and undercooked foods can lead to disease.</p><p>A powerful vaccination campaign is imperative for prevention. Globally, vaccines against Measles, Meningococcal Meningitis and Yellow Fever are the most important to public health. Cholera vaccines can also be used.</p><p>Measles requires 96% coverage for herd immunity to be established, and so with an outbreak of any disease, if the affected population is vaccinated &#x0003c;90% for measles, then prioritizing measles vaccination is necessary. Additionally, prioritize measles vaccines based on age, specifically, between 6 months and 14 years of age.</p><p>Epidemic Meningitis can occur in crowded conditions, and is most commonly caused by Neisseria meningitidis. The vaccines for several serogroups of this pathogen last about 5 years (2 years in children), and it is 90% effective in those older than 2 years old. Children aged 2-10 years old are the most at risk.</p><p>Yellow fever is only deadly in 5%, but the vaccination is effective in 95%, and lasts 10 years or more. The viral disease is transmitted by mosquitos and can have high morbidity when concurrent with other disease outbreak. It should not be given to symptomatic HIV-infected persons. The vaccine has a significant side-effect profile (fever, headache, myalgia) as compared to other vaccines.</p><p>Oral cholera vaccines are available for those travelling to endemic areas as well as to people involved in emergency conditions. 2 doses of the oral cholera vaccine can be up to 65% effective for up to 5 years according to the most recent research.<xref rid="bib10" ref-type="bibr"><sup>[10]</sup></xref></p></sec><sec id="cesec60"><title>Surveillance</title><p>&#x0201c;Surveillance and early warning systems&#x0201d; should be set up in emergency conditions. This involves watching diseases on a continuum, finding trends, and reporting outbreaks earlier rather than later. This is a data collection phase, similar to the rapid assessment phase, but on a larger scale, and primarily involves interpretation of the data collected in order to create an efficient and effective public health response to the threat.</p></sec><sec id="cesec70"><title>Outbreak Control</title><p>In summary, &#x0201c;outbreak control&#x0201d; involves &#x0201c;preparation, detection, confirmation, response, and evaluation.&#x0201d; Epidemics can be defined as outbreaks and vice versa according to the WHO. The first step of &#x0201c;preparation&#x0201d; covers much of what we have already discussed: setting up camp with isolation wards, gathering stockpiles of treatment supplies (medicines, vaccinations, tools), and collecting competent healthcare workers as well as a laboratory. Next, &#x0201c;detection&#x0201d; involves the development of an early warning system for epidemics such as acute watery diarrhea, measles, and others using laboratory confirmation, or clinical diagnosis as well as epidemiology to assess if the statistical analysis of the cases meets outbreak standards. &#x0201c;Response&#x0201d; involves confirming the diagnosis, formulating a hypothesis for the source, pathogen, and method of transmission, writing an investigation report, and ultimately, controlling the event by treatment, but moreover, prevention specific to the disease. Lastly, &#x0201c;evaluation&#x0201d; involves changing public health policies as needed, writing an outbreak report, and assessing the previous steps in detail in terms of success and appropriateness.</p></sec><sec id="cesec80"><title>Notable Communicable Diseases</title><p>This section describes key features in bulletpoint form regarding a small selection of notable communicable diseases worldwide. Due to the enormous amount of information on this subject, several significant diseases will not be discussed such as meningitis, and pneumonia. Most of the information presented is adapted from the &#x0201c;Control of Communicable Diseases Manual&#x0201d; 20th Edition edited by Dr. Heymann. Please consult this manual for in-depth information, and a more exhaustive list.<xref rid="bib10" ref-type="bibr"><sup>[10]</sup></xref></p></sec><sec id="cesec90"><title>Cholera</title><p><list list-type="simple"><list-item id="celistitem10"><label>&#x02022;</label><p>Significant epidemics with <italic>Vibrio cholerae</italic> subgroups: O1 and O139.</p></list-item><list-item id="celistitem20"><label>&#x02022;</label><p>Bacterial infection of bowels.</p></list-item><list-item id="celistitem30"><label>&#x02022;</label><p>Clinical: sudden onset, profuse, clear diarrhea. If untreated, can lead to acidosis, hypovolemic shock, and renal failure in addition to other end-organ damage.</p></list-item><list-item id="celistitem40"><label>&#x02022;</label><p>Associated with natural disasters, overcrowding, poor hygiene, and soiled water supply.</p></list-item><list-item id="celistitem50"><label>&#x02022;</label><p>Diagnosis: stool culture, or microscopic examination of stool for &#x0201c;shooting stars.&#x0201d;
<list list-type="simple"><list-item id="celistitem60"><label>&#x02218;</label><p>During epidemics, cholera should be presumed after the first batch of confirmed cases, by history and exam alone, and money should not be spent confirming every case of cholera thereafter.</p></list-item></list></p></list-item><list-item id="celistitem70"><label>&#x02022;</label><p>Incubation: 2-3 days.</p></list-item><list-item id="celistitem80"><label>&#x02022;</label><p>Transmission: consumption of water, or food contaminated with feces of infected persons.</p></list-item><list-item id="celistitem90"><label>&#x02022;</label><p>Vaccinations: as discussed in previous section.</p></list-item><list-item id="celistitem100"><label>&#x02022;</label><p>Management:
<list list-type="simple"><list-item id="celistitem110"><label>&#x02218;</label><p>Strict isolation is not important although hygiene and handwashing is crucial.</p></list-item><list-item id="celistitem120"><label>&#x02218;</label><p>Rehydration is key. Less severe cases can be managed with oral rehydration solution (ORS) alone. Moderate to severe cases must be managed with intravenous fluid.</p></list-item><list-item id="celistitem130"><label>&#x02218;</label><p>In severe cases, doxycycline, or other antibiotics, can be used.</p></list-item></list></p></list-item></list></p></sec><sec id="cesec100"><title>Ebola and Marburg (Viral Hemorrhagic Fever)</title><p><list list-type="simple"><list-item id="celistitem140"><label>&#x02022;</label><p>Acute viral (negative stranded RNA viruses: <italic>Filoviridae</italic>) illness.</p></list-item><list-item id="celistitem150"><label>&#x02022;</label><p>Clinical: fever, malaise, myalgia, headache, sore throat, diarrhea, vomiting, non-specific rash.</p></list-item><list-item id="celistitem160"><label>&#x02022;</label><p>Severe or fatal progression is possible (32-88% for Ebola, 22-90% for Marburg): hemorrhagic diathesis and shock.</p></list-item><list-item id="celistitem170"><label>&#x02022;</label><p>Diagnosis: multiple methods available via blood or tissue samples (PCR, ELISA, immunohistochemistry, detection of IgM or rising IgG).
<list list-type="simple"><list-item id="celistitem180"><label>&#x02218;</label><p>Labs: lymphopenia, thrombocytopenia, transaminitis, creatinine elevation, uremia.</p></list-item><list-item id="celistitem190"><label>&#x02218;</label><p>A recent article describes an evidence-based method to diagnose Ebola infection without relying fully on laboratory tests (in a highly endemic area of West Africa). The 6 items that were shown to be predictive of a positive laboratory confirmation of Ebola: &#x0201c;sick contacts, diarrhea, loss of appetite, muscle pains, difficulty swallowing, and absence of abdominal pain.&#x0201d; This can help avoid nosocomial spread of the disease, minimizing unnecessary contact with infected bodily fluids by healthcare providers.<xref rid="bib11" ref-type="bibr"><sup>[11]</sup></xref></p></list-item></list></p></list-item><list-item id="celistitem200"><label>&#x02022;</label><p>Largest outbreak to date in 2014: Guinea, Liberia, Sierra Leone, Nigeria, and Senegal with almost 4,000 confirmed or suspected cases as well as almost 2,000 deaths (as of 08/31/2014).</p></list-item><list-item id="celistitem210"><label>&#x02022;</label><p>Reservoir: unclear, but proposed to be forest (or cave for Marburg) fruit bats.</p></list-item><list-item id="celistitem220"><label>&#x02022;</label><p>Incubation: 5-15 days.</p></list-item><list-item id="celistitem230"><label>&#x02022;</label><p>Transmission: Person to person. Direct contact with infected blood, urine, vomit, diarrhea, semen (Ebola virus has been isolated in semen for up to 61 days), organs, and virtually any secretions. Care must be taken during funerals because the virus will still be active in a deceased person. Highest risk exists in late stages of illness. It has not been documented if the virus is transmitted via airborne routes.</p></list-item><list-item id="celistitem240"><label>&#x02022;</label><p>No approved vaccine exists yet.</p></list-item><list-item id="celistitem250"><label>&#x02022;</label><p>Management:
<list list-type="simple"><list-item id="celistitem260"><label>&#x02218;</label><p>Strict isolation of patients, their secretions, and their deceased body, at the highest level of biohazard precautions. Laboratory tests and contact in general should be kept at a minimum. Only essential interaction with patient should occur until the virus has been cleared from their body. Disinfect all equipment and patient secretions with 0.5% sodium hypochlorite solution, or 0.5% phenol with detergent as well as the use of incineration, or autoclave.</p></list-item><list-item id="celistitem270"><label>&#x02218;</label><p>No approved anti-viral treatment exists yet.</p></list-item><list-item id="celistitem280"><label>&#x02218;</label><p>Supportive care.</p></list-item></list></p></list-item></list></p></sec><sec id="cesec110"><title>Hantavirus</title><p><list list-type="simple"><list-item id="celistitem290"><label>&#x02022;</label><p>Zoonotic disease.</p></list-item><list-item id="celistitem300"><label>&#x02022;</label><p><italic>Bunyaviridae virus.</italic></p></list-item><list-item id="celistitem310"><label>&#x02022;</label><p>Two different syndromes.
<list list-type="simple"><list-item id="celistitem320"><label>&#x02218;</label><p>Shared features: fever prodrome, thrombocytopenia, and leukocytosis.</p></list-item><list-item id="celistitem330"><label>&#x02218;</label><p>Hemorrhagic Fever with Renal Syndrome (HFRS): fever for 3-7 days then severe back or abdominal pain, hypotension/shock, oliguria/renal failure, diuresis, then a long protracted convalescence phase if the patient survives.</p></list-item><list-item id="celistitem340"><label>&#x02218;</label><p>Hantavirus Pulmonary Syndrome (HPS): pulmonary edema/respiratory distress and shock. More fatal than HFRS.</p></list-item></list></p></list-item><list-item id="celistitem350"><label>&#x02022;</label><p>Diagnosis: IgG and IgM in serum. Virus usually not detectable.</p></list-item><list-item id="celistitem360"><label>&#x02022;</label><p>Reservoir: rodents.</p></list-item><list-item id="celistitem370"><label>&#x02022;</label><p>Incubation: 2-4 weeks. Faster for HPS (2 weeks).</p></list-item><list-item id="celistitem380"><label>&#x02022;</label><p>Transmission: aerosol from rodent excrement most likely.</p></list-item><list-item id="celistitem390"><label>&#x02022;</label><p>Prevention: rodent control, disinfect rodent infested areas, vaccine (only available for Hantaan and Seoul viruses).</p></list-item><list-item id="celistitem400"><label>&#x02022;</label><p>Treatment: supportive care. Dialysis for HFRS. Ribvarin in some early cases. Avoid supplementing too much fluids with HPS. Respiratory ICU level of care for HPS.</p></list-item></list></p></sec><sec id="cesec120"><title>Hepatitis</title><p><list list-type="simple"><list-item id="celistitem410"><label>&#x02022;</label><p>Viral.
<list list-type="simple"><list-item id="celistitem420"><label>&#x02218;</label><p>Several types: A, B, C, D, E.</p></list-item><list-item id="celistitem430"><label>&#x02218;</label><p>Clinical findings: abdominal pain, nausea, anorexia, fevers progressing to jaundice, transaminitis.</p></list-item></list></p></list-item><list-item id="celistitem440"><label>&#x02022;</label><p>Hepatitis A (<italic>Picornaviridae</italic>, +RNA virus):
<list list-type="simple"><list-item id="celistitem450"><label>&#x02218;</label><p>Acute only. Not chronic.</p></list-item><list-item id="celistitem460"><label>&#x02218;</label><p>Spreads rapidly in emergency conditions.</p></list-item><list-item id="celistitem470"><label>&#x02218;</label><p>Can last 1 year in a minority of cases.</p></list-item><list-item id="celistitem480"><label>&#x02218;</label><p>Low fatality rate.</p></list-item><list-item id="celistitem490"><label>&#x02218;</label><p>Incubation: 30 days average</p></list-item><list-item id="celistitem500"><label>&#x02218;</label><p>Transmission: Fecal-oral route.</p></list-item><list-item id="celistitem510"><label>&#x02218;</label><p>Prevention: sanitation, hygiene, water supply, vaccine if in epidemic area, immunoglobulin in special cases.</p></list-item><list-item id="celistitem520"><label>&#x02218;</label><p>Management: supportive.</p></list-item></list></p></list-item><list-item id="celistitem530"><label>&#x02022;</label><p>Hepatitis B (<italic>Hepadnavirus,</italic> dsDNA virus);
<list list-type="simple"><list-item id="celistitem540"><label>&#x02218;</label><p>Acute infection, but can progress to chronic. Can result in hepatocellular carcinoma, cirrhosis.</p></list-item><list-item id="celistitem550"><label>&#x02218;</label><p>Diagnosis: analysis of antigens and antibodies to different components of the virus in the serum.</p></list-item><list-item id="celistitem560"><label>&#x02218;</label><p>2 billion persons infected globally by WHO estimates.</p></list-item><list-item id="celistitem570"><label>&#x02218;</label><p>Incubation: 2-3 months.</p></list-item><list-item id="celistitem580"><label>&#x02218;</label><p>Transmission: bodily fluid exposure, and even up to 7 days outside of human reservoirs on objects.</p></list-item><list-item id="celistitem590"><label>&#x02218;</label><p>Prevention: vaccine, blood bank control.</p></list-item><list-item id="celistitem600"><label>&#x02218;</label><p>Treatment: supportive. In some cases, although high cost, anti-viral medications can be given.</p></list-item></list></p></list-item><list-item id="celistitem610"><label>&#x02022;</label><p>Hepatitis C (<italic>Hepacivirus,</italic> of the <italic>Flaviviridae,</italic> enveloped RNA virus):
<list list-type="simple"><list-item id="celistitem620"><label>&#x02218;</label><p>75% become chronic infections. 20% of these will develop cirrhosis over 20 years. Some will develop hepatocellular carcinoma.</p></list-item><list-item id="celistitem630"><label>&#x02218;</label><p>Diagnosis: analysis of antigens and antibodies to HCV.</p></list-item><list-item id="celistitem640"><label>&#x02218;</label><p>150 million people are chronically infected with HCV according to WHO.</p></list-item><list-item id="celistitem650"><label>&#x02218;</label><p>Incubation: 6-9 weeks average.</p></list-item><list-item id="celistitem660"><label>&#x02218;</label><p>Transmission: parenteral (at-risk populations: drug abusers sharing needles, those receiving blood products frequently, hemodialysis patients)</p></list-item><list-item id="celistitem670"><label>&#x02218;</label><p>Prevention: no vaccine. Blood bank control. Needle exchange.</p></list-item><list-item id="celistitem680"><label>&#x02218;</label><p>Management: supportive. Anti-viral medications can clear the infection in some cases.</p></list-item></list></p></list-item><list-item id="celistitem690"><label>&#x02022;</label><p>Hepatitis D (delta antigen of Hepatitis B)
<list list-type="simple"><list-item id="celistitem700"><label>&#x02218;</label><p>Requires co-infection with Hepatitis B.</p></list-item><list-item id="celistitem710"><label>&#x02218;</label><p>More severe form of Hepatitis B.</p></list-item></list></p></list-item><list-item id="celistitem720"><label>&#x02022;</label><p>Hepatitis E (<italic>Hepeviridae,</italic> single-stranded RNA virus)
<list list-type="simple"><list-item id="celistitem730"><label>&#x02218;</label><p>Similar to Hepatitis A, but shorter course.</p></list-item><list-item id="celistitem740"><label>&#x02218;</label><p>High mortality in pregnant women.</p></list-item><list-item id="celistitem750"><label>&#x02218;</label><p>Co-infection indicates higher infectivity of Hepatitis B in adults.</p></list-item></list></p></list-item></list></p></sec><sec id="cesec130"><title>HIV/AIDS</title><p><list list-type="simple"><list-item id="celistitem760"><label>&#x02022;</label><p>Acquired Immune Deficiency Syndrome (AIDS) results from chronic infection with Human Immunodeficiency Virus (HIV).</p></list-item><list-item id="celistitem770"><label>&#x02022;</label><p>Multiple infections result from AIDS including severe pneumonia, diarrhea, and many others.</p></list-item><list-item id="celistitem780"><label>&#x02022;</label><p>Retrovirus.</p></list-item><list-item id="celistitem790"><label>&#x02022;</label><p>Flu-like illness within the first several weeks of infection, followed by several years of dormancy, followed by AIDS with a sharp decline in CD4 cells in untreated patients.</p></list-item><list-item id="celistitem800"><label>&#x02022;</label><p>Diagnosis: detection of antibodies and/or antigens. Viral load also useful.</p></list-item><list-item id="celistitem810"><label>&#x02022;</label><p>35 million persons living with infection of HIV worldwide with 70% living in Sub-Saharan Africa.</p></list-item><list-item id="celistitem820"><label>&#x02022;</label><p>Transmission: blood primarily, and other bodily fluids (penile-vaginal, penile-anal, dirty needle, mother to infant during pregnancy, transfusion). Risk increases with higher viral loads.</p></list-item><list-item id="celistitem830"><label>&#x02022;</label><p>If latent TB and HIV, 6-8 times higher chance of progressing to active TB.</p></list-item><list-item id="celistitem840"><label>&#x02022;</label><p>Prevention: education regarding safe needle use, safe sex, pregnancy and HIV. Post-exposure prophylaxis. Blood bank control.</p></list-item><list-item id="celistitem850"><label>&#x02022;</label><p>Management: Three-drug antiretroviral regimen is recommended lifelong. Prophylactic medications based on CD4 counts. Antibiotic treatments for specific infections (ie: TB).</p></list-item></list></p></sec><sec id="cesec140"><title>Influenza</title><p><list list-type="simple"><list-item id="celistitem860"><label>&#x02022;</label><p>Acute viral illness primarily of the upper respiratory tract.</p></list-item><list-item id="celistitem870"><label>&#x02022;</label><p>Symptoms: fever, myalgia, dry cough, headache, sore throat. In children, gastrointestinal symptoms may be present as well.</p></list-item><list-item id="celistitem880"><label>&#x02022;</label><p>Complication: Lower respiratory tract extension. Superimposed bacterial pneumonia (<italic>Streptococcus pneumoniae,</italic> or S. <italic>aureus</italic> with large proportion being MRSA).</p></list-item><list-item id="celistitem890"><label>&#x02022;</label><p>90% of deaths are in elderly. Children under 2 years old at high risk as well. Some strains of Influenza can cause severe disease in healthy, young people.</p></list-item><list-item id="celistitem900"><label>&#x02022;</label><p>Current types of Influenza that are included in seasonal vaccine: subtypes of Influenza A (H1N1 and H3N2), and Influenza B.
<list list-type="simple"><list-item id="celistitem910"><label>&#x02218;</label><p>Antigenic drift requires a biannual review to change the vaccine.</p></list-item><list-item id="celistitem920"><label>&#x02218;</label><p>Antigenic shift is more disastrous to public health, and can result in a pandemic.</p></list-item></list></p></list-item><list-item id="celistitem930"><label>&#x02022;</label><p>Diagnosis: history and physical as well as RT-PCR via upper respiratory swab (most commonly nasopharyngeal).</p></list-item><list-item id="celistitem940"><label>&#x02022;</label><p>Incubation: 2 days.</p></list-item><list-item id="celistitem950"><label>&#x02022;</label><p>Transmission: droplet, and contact.</p></list-item><list-item id="celistitem960"><label>&#x02022;</label><p>Prevention: Education, and vaccination.</p></list-item><list-item id="celistitem970"><label>&#x02022;</label><p>Management: isolation of patient, and early administration of neuraminidase inhibitors (within 48 hours of symptom onset) for those at high risk (immunosuppressed, elderly), supportive care.</p></list-item></list></p></sec><sec id="cesec150"><title>Malaria</title><p><list list-type="simple"><list-item id="celistitem980"><label>&#x02022;</label><p>Protozoan parasites: <italic>Plasmodium falciparum, P. vivax,</italic> ovale, and malariae.</p></list-item><list-item id="celistitem990"><label>&#x02022;</label><p>Acute febrile disease: cyclic fevers with almost any symptom present from cough to abdominal pain to headaches.</p></list-item><list-item id="celistitem1000"><label>&#x02022;</label><p>P. <italic>falciparum</italic> malaria
<list list-type="simple"><list-item id="celistitem1010"><label>&#x02218;</label><p>Severe. Often fatal if not treated.</p></list-item><list-item id="celistitem1020"><label>&#x02218;</label><p>Unique, differentiating factors: decreased sensorium, seizures, respiratory distress, shock.</p></list-item></list></p></list-item><list-item id="celistitem1030"><label>&#x02022;</label><p>Other causes of malaria
<list list-type="simple"><list-item id="celistitem1040"><label>&#x02218;</label><p>Usually not fatal, but patients are often significantly ill.</p></list-item><list-item id="celistitem1050"><label>&#x02218;</label><p>Cyclic fevers can occur up to 4 years due to parasite living in liver if untreated.</p></list-item></list></p></list-item><list-item id="celistitem1060"><label>&#x02022;</label><p>Diagnosis:
<list list-type="simple"><list-item id="celistitem1070"><label>&#x02218;</label><p>WHO recommendation: every suspected case should be tested.</p></list-item><list-item id="celistitem1080"><label>&#x02218;</label><p>Microscopy: visualize parasites directly on blood smear.</p></list-item><list-item id="celistitem1090"><label>&#x02218;</label><p>RDT (rapid diagnostic test), PCR assays.</p></list-item><list-item id="celistitem1100"><label>&#x02218;</label><p>Serologic tests are not recommended because they cannot detect active infection.</p></list-item></list></p></list-item><list-item id="celistitem1110"><label>&#x02022;</label><p>660 thousand deaths reported in 2010, mostly in Africa.</p></list-item><list-item id="celistitem1120"><label>&#x02022;</label><p>Incubation: 2 weeks for <italic>P. falciparum,</italic> and slightly longer for the others.</p></list-item><list-item id="celistitem1130"><label>&#x02022;</label><p>Transmission: bite of female <italic>Anopheles</italic> mosquito, which usually feeds at night, infects a human, which in turn, infects other mosquitos that feed on the human, which can then infect humans once again.</p></list-item><list-item id="celistitem1140"><label>&#x02022;</label><p>Prevention: previously mentioned in vector control above.</p></list-item><list-item id="celistitem1150"><label>&#x02022;</label><p>Management: anti-malarial antibiotics and supportive care. Drug resistance is an issue. Refer to most appropriate and up to date management. Promptly treat <italic>P. falciparum</italic>.</p></list-item></list></p></sec><sec id="cesec160"><title>Measles</title><p><list list-type="simple"><list-item id="celistitem1160"><label>&#x02022;</label><p>Acute viral disease.</p></list-item><list-item id="celistitem1170"><label>&#x02022;</label><p>Measles virus <italic>(Morbillivirus</italic> of <italic>Paramyxoviridae).</italic></p></list-item><list-item id="celistitem1180"><label>&#x02022;</label><p>Clinical: Prodrome of fever.
<list list-type="simple"><list-item id="celistitem1190"><label>&#x02218;</label><p>Cough, coryza, conjunctivitis, and Koplik spots.</p></list-item><list-item id="celistitem1200"><label>&#x02218;</label><p>Rash on day 3-7. Spreads from head to rest of body.</p></list-item></list></p></list-item><list-item id="celistitem1210"><label>&#x02022;</label><p>Complications: bacterial superinfections (pneumonia, otitis media, and others).</p></list-item><list-item id="celistitem1220"><label>&#x02022;</label><p>Diagnosis: IgM and IgG (greater than 4 fold rise) detection, PCR.
<list list-type="simple"><list-item id="celistitem1230"><label>&#x02218;</label><p>Labs: leukopenia. Vitamin A levels are often low.</p></list-item></list></p></list-item><list-item id="celistitem1240"><label>&#x02022;</label><p>Incubation: 14 days.</p></list-item><list-item id="celistitem1250"><label>&#x02022;</label><p>Transmission: airborne droplet, upper respiratory secretions.</p></list-item><list-item id="celistitem1260"><label>&#x02022;</label><p>Prevention: vaccine is highly effective. Measles epidemics declined in the 1990s, but even with 90% immunization coverage, there can be significant outbreaks during an emergency condition. This is even more apparent when measles immunization coverage is low such as in Ethiopia, and Afghanistan.<xref rid="bib3" ref-type="bibr"><sup>[3]</sup></xref></p></list-item><list-item id="celistitem1270"><label>&#x02022;</label><p>Management: isolation, vitamin A supplementation, primarily supportive.</p></list-item></list></p></sec><sec id="cesec170"><title>SARS, MERS</title><p><list list-type="simple"><list-item id="celistitem1280"><label>&#x02022;</label><p>Coronaviruses (CoV).
<list list-type="simple"><list-item id="celistitem1290"><label>&#x02218;</label><p>Enveloped single stranded positive RNA</p></list-item></list></p></list-item><list-item id="celistitem1300"><label>&#x02022;</label><p>SARS (Severe Acute Respiratory Syndrome), SARS-CoV:
<list list-type="simple"><list-item id="celistitem1310"><label>&#x02218;</label><p>Viral pneumonia with bilateral infiltrates reminiscent of Acute Respiratory Distress Syndrome (ARDS).</p></list-item><list-item id="celistitem1320"><label>&#x02218;</label><p>30% required ICU level of care. Rapid progression to respiratory failure after day 10.</p></list-item><list-item id="celistitem1330"><label>&#x02218;</label><p>November 2002 was the first case, and the outbreak, around Southern China, lasted until 2004.</p></list-item><list-item id="celistitem1340"><label>&#x02218;</label><p>Diagnosis: PCR is available for sputum, urine and stool, but is not fully reliable. Since 2004, there has not been any documented SARS-CoV infection so testing is not available in most places.</p></list-item><list-item id="celistitem1350"><label>&#x02218;</label><p>Reservoir: likely the Himalayan masked palm civet (<italic>Paguma larvata</italic>).</p></list-item><list-item id="celistitem1360"><label>&#x02218;</label><p>Incubation: 5 days.</p></list-item><list-item id="celistitem1370"><label>&#x02218;</label><p>Transmission: person to person via contact and respiratory secretions.</p></list-item><list-item id="celistitem1380"><label>&#x02218;</label><p>Management: treat for pneumonia until proven otherwise.</p></list-item></list></p></list-item><list-item id="celistitem1390"><label>&#x02022;</label><p>Fully isolate with contact and airborne precautions if SARS-CoV is suspected to have reemerged.</p></list-item><list-item id="celistitem1400"><label>&#x02022;</label><p>MERS (Middle East Respiratory Syndrome), MERS-CoV:
<list list-type="simple"><list-item id="celistitem1410"><label>&#x02218;</label><p>2012 emergence in Saudi Arabia.</p></list-item><list-item id="celistitem1420"><label>&#x02218;</label><p>Viral pneumonia.</p></list-item><list-item id="celistitem1430"><label>&#x02218;</label><p>Clinical: Fever, and cough. Severe respiratory distress requiring intubation. More recently, milder cases have been diagnosed, but mortality is 40% in severe cases, especially in patients with comorbidities such as heart disease, and immunosuppression.</p></list-item><list-item id="celistitem1440"><label>&#x02218;</label><p>Diagnosis: sputum samples and serum should be tested via rapid real-time PCR. Test all suspected cases (significant respiratory symptoms in patients that have traveled to, or reside in, the middle east).</p></list-item><list-item id="celistitem1450"><label>&#x02218;</label><p>Reservoir: unknown. Possibly bats, or dromedary camels.</p></list-item><list-item id="celistitem1460"><label>&#x02218;</label><p>Incubation: unknown, estimated at 2-14 days.</p></list-item><list-item id="celistitem1470"><label>&#x02218;</label><p>Transmission: unknown, but likely similar to SARS-CoV.</p></list-item><list-item id="celistitem1480"><label>&#x02218;</label><p>Prevention: Use N95 respirator, and maximum contact/airborne precautions, when treating, and in particular, intubating, a patient suspected of MERS-CoV. No vaccine available.</p></list-item><list-item id="celistitem1490"><label>&#x02218;</label><p>Management:</p></list-item></list></p></list-item><list-item id="celistitem1500"><label>&#x02022;</label><p>Fully isolate with contact and airborne precautions.</p></list-item><list-item id="celistitem1510"><label>&#x02022;</label><p>Antibiotics for pneumonia until proven otherwise.</p></list-item><list-item id="celistitem1520"><label>&#x02022;</label><p>No antiviral treatment exists.</p></list-item><list-item id="celistitem1530"><label>&#x02022;</label><p>Supportive care.</p></list-item></list></p></sec><sec id="cesec180"><title>Tuberculosis</title><p><list list-type="simple"><list-item id="celistitem1540"><label>&#x02022;</label><p><italic>Mycobacterium tuberculosis.</italic></p></list-item><list-item id="celistitem1550"><label>&#x02022;</label><p>Latent and Active (pulmonary and extrapulmonary) forms.</p></list-item><list-item id="celistitem1560"><label>&#x02022;</label><p>Clinical: cough, fevers, weight loss.</p></list-item><list-item id="celistitem1570"><label>&#x02022;</label><p>Fibrosis of lungs in advanced disease.</p></list-item><list-item id="celistitem1580"><label>&#x02022;</label><p>Diagnosis of active TB: traditional is obtaining at least 2 sputum specimens showing acid-fast bacilli (AFB). More recently is using the Xpert MTB/RIF molecular test. Chest x-ray can show cavitations in the upper lobes.</p></list-item><list-item id="celistitem1590"><label>&#x02022;</label><p>In 2011, there were 1.4 million deaths from TB despite a slow decline in the global incidence since the early 2000s.<xref rid="bib12" ref-type="bibr"><sup>[12]</sup></xref></p></list-item><list-item id="celistitem1600"><label>&#x02022;</label><p>Multi drug-resistant (MDR) and extensively drug-resistant (XDR-TB) are major threats.<xref rid="bib12" ref-type="bibr"><sup>[12]</sup></xref></p></list-item><list-item id="celistitem1610"><label>&#x02022;</label><p>Incubation: not readily known. HIV and immunosuppression causes a more rapid progression from latent to active TB.</p></list-item><list-item id="celistitem1620"><label>&#x02022;</label><p>Transmission: airborne droplet nuclei, respiratory secretions.</p></list-item><list-item id="celistitem1630"><label>&#x02022;</label><p>Prevention: no reliable vaccine available. Education is paramount. Treatment of latent TB.</p></list-item><list-item id="celistitem1640"><label>&#x02022;</label><p>Management:
<list list-type="simple"><list-item id="celistitem1650"><label>&#x02218;</label><p>Strict airborne isolation.</p></list-item><list-item id="celistitem1660"><label>&#x02218;</label><p>Prompt treatment with antibiotics based on the most up to date recommendations.</p></list-item><list-item id="celistitem1670"><label>&#x02218;</label><p>Supportive care.</p></list-item></list></p></list-item></list></p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name><surname>Babaie</surname><given-names>J</given-names></name><name><surname>Ardalan</surname><given-names>A</given-names></name><name><surname>Vatandoost</surname><given-names>H</given-names></name><name><surname>Goya</surname><given-names>MM</given-names></name><name><surname>Akbarisari</surname><given-names>A</given-names></name></person-group><article-title>Performance assessment of communicable disease surveillance in disasters: a systematic review</article-title><source>PLoS Curr</source><year>2015</year><fpage>7</fpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>MA</given-names></name><name><surname>Heymann</surname><given-names>DL</given-names></name></person-group><article-title>Deadly comrades: war and infectious diseases</article-title><source>Lancet</source><volume>360</volume><issue>Suppl</issue><year>2002</year><fpage>23</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12114037</pub-id></element-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="other" id="oref10">Abdallah S. Control of communicable diseases. Public Health Guide for Emergencies, The Johns Hopkins and the International Federation of Red Cross and Red Crescent Societies. 2nd edition. 2008</mixed-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>SY</given-names></name><name><surname>Theodoro</surname><given-names>DL</given-names></name><name><surname>Schuur</surname><given-names>JD</given-names></name><name><surname>Marschall</surname><given-names>J</given-names></name></person-group><article-title>Infection prevention in the emergency department</article-title><source>Ann Emerg Med</source><volume>64</volume><year>2014</year><fpage>299</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">24721718</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>JD</given-names></name><name><surname>Rhinehart</surname><given-names>E</given-names></name><name><surname>Jackson</surname><given-names>M</given-names></name><name><surname>Chiarello</surname><given-names>L</given-names></name><name><surname>Health Care Infection Control Practices Advisory Committee</surname></name></person-group><article-title>2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings</article-title><source>Am J Infect Control</source><volume>35</volume><issue>10 Suppl 2</issue><year>2007</year><fpage>65</fpage><lpage>164</lpage></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref50"><person-group person-group-type="author"><name><surname>Behrman</surname><given-names>AJ</given-names></name><name><surname>Shofer</surname><given-names>FS</given-names></name></person-group><article-title>Tuberculosis exposure and control in an urban emergency department</article-title><source>Ann Emerg Med</source><volume>31</volume><year>1998</year><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">9506496</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref60"><person-group person-group-type="author"><name><surname>Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC)</surname></name></person-group><article-title>Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title><source>MMWR Recomm Rep</source><volume>60</volume><year>2011</year><fpage>1</fpage><lpage>45</lpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="book" id="sbref70"><person-group person-group-type="author"><name><surname>Connolly</surname><given-names>MA</given-names></name></person-group><source>Communicable disease control in emergencies: A field manual</source><year>2005</year><publisher-name>WHO World Health Organization</publisher-name></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref80"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>PA</given-names></name><name><surname>Reed</surname><given-names>RA</given-names></name></person-group><article-title>Planning environmental sanitation programmes in emergencies</article-title><source>Disasters</source><volume>29</volume><year>2005</year><fpage>129</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">15910646</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="book" id="sbref90"><person-group person-group-type="author"><name><surname>Heymann</surname><given-names>DL</given-names></name></person-group><source>Control of communicable diseases</source><edition>20th edition</edition><year>2015</year><publisher-name>APHA. Offficial Report of the American Public Health Association</publisher-name></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref100"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>AC</given-names></name><name><surname>Shetty</surname><given-names>PP</given-names></name><name><surname>Burbach</surname><given-names>R</given-names></name><name><surname>Cheemalapati</surname><given-names>S</given-names></name><name><surname>Glavis-Bloom</surname><given-names>J</given-names></name><name><surname>Wiskel</surname><given-names>T</given-names></name></person-group><article-title>Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients With Suspected Ebola Virus Disease</article-title><source>Ann Emerg Med</source><volume>66</volume><year>2015</year><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">25845607</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref110"><person-group person-group-type="author"><name><surname>Christian</surname><given-names>KA</given-names></name><name><surname>Ijaz</surname><given-names>K</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>Chow</surname><given-names>CC</given-names></name><name><surname>Chitale</surname><given-names>RA</given-names></name><name><surname>Bresee</surname><given-names>JS</given-names></name></person-group><article-title>What we are watching-five top global infectious disease threats, 2012: a perspective from CDC's Global Disease Detection Operations Center</article-title><source>Emerg Health Threats J</source><volume>6</volume><year>2013</year><fpage>20632</fpage><pub-id pub-id-type="pmid">23827387</pub-id></element-citation></ref></ref-list></back></article>